Novo Nordisk's investor relations highlighted that the launch of its oral semaglutide is progressing with dose escalation patterns differing from its injectable forms. Despite improved data capture at 65%, 90% of prescriptions are still paid out-of-pocket rather than through insurance. The injectable market faces intense competition, with Canadian prices discounted 40-65% and compounded semaglutide supply peaking but remaining significant with 1.5 million patients still using it. Deutsche Bank maintains a hold rating on Novo Nordisk, reflecting balanced risks amid pricing pressures and pipeline developments.
June is proving to be a month for stock pickers focusing on three large-cap companies trading well below their highs but showing signs of recovery. Lululemon is down 46% year-to-date, facing challenges in North America but buoyed by strong internatio...
A Rutgers University study found that GLP-1 medications like Ozempic and Wegovy may reduce violent behavior risk by weakening the link between impulsivity, alcohol use, and violence. The study analyzed data from 7,521 U.S. adults, focusing on 821 GLP...
GLP-1 drugs for weight loss are rapidly expanding worldwide, with Novo Nordisk's Wegovy® pill reaching over three million prescriptions since January 2026 and launching in the UAE and UK. Eli Lilly's investigational drug retatrutide shows significant...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
Novo Nordisk has regained investor confidence driven by strong demand for its Wegovy weight loss pill, which is helping stabilize its market share. While the company expects a 7% sales decline in 2024 due to U.S. pricing pressures, its international ...
